XOMA
XOMA Royalty Corporation
Price Chart
Latest Quote
$42.09
-0.31 (-0.73%)
Current Price
| Previous Close | $42.40 |
| Open | $42.30 |
| Day High | $42.30 |
| Day Low | $42.02 |
| Volume | 41,939 |
Stock Information
| Shares Outstanding | 12.54M |
| Total Debt | $124.73M |
| Cash Equivalents | $86.09M |
| Revenue | $48.55M |
| Net Income | $19.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $527.85M |
| P/E Ratio | 26.81 |
| EPS (TTM) | $1.57 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $586.56M |
| Sales | $48.55M |
| Income | $19.93M |
| Book/sh | $7.07 |
| Cash/sh | $6.86 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 3.31 |
| Current Ratio | 3.59 |
| Debt/Eq | 110.48 |
| EPS Growth TTM | 88.60% |
Returns & Margins
| ROA | 1.28% |
| ROE | 34.23% |
| Gross Margin | 99.04% |
| Operating Margin | -3.90% |
| Profit Margin | 69.63% |
Ownership
| Insider Ownership | 4.14% |
| Institutional Ownership | 119.90% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 19.67 |
| P/S | 10.87 |
| P/B | 5.95 |
Analyst Data
| Recommendation | hold |
| Target Price | $39.00 |
Technical Indicators
| SMA20 | $41.79 |
| SMA50 | $39.29 |
| SMA200 | $32.86 |
| RSI | 57.87 |
| ATR | 0.3157 |
| Shares Float | 882K |
| Short Float | 11.56% |
| Short Ratio | 2.14 |
| Volatility | 0.87 |
| Rel Volume | 0.41 |
Performance History
| Week | +0.91% |
| Month | +1.18% |
| Quarter | +62.01% |
| 6 Months | +35.77% |
| YTD | +50.38% |
| Year | +68.36% |
| 3 Years | +147.59% |
| 5 Years | +42.82% |
| 10 Years | +205.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $42.09 | 42,000 |
| 2026-06-04 | $42.40 | 133,400 |
| 2026-06-03 | $41.70 | 67,900 |
| 2026-06-02 | $41.69 | 79,500 |
| 2026-06-01 | $41.69 | 119,300 |
| 2026-05-29 | $41.71 | 78,300 |
| 2026-05-28 | $41.70 | 249,000 |
| 2026-05-27 | $41.74 | 45,200 |
| 2026-05-26 | $41.72 | 67,600 |
| 2026-05-22 | $41.65 | 124,800 |
| 2026-05-21 | $41.82 | 52,200 |
| 2026-05-20 | $41.98 | 111,400 |
| 2026-05-19 | $41.54 | 121,700 |
| 2026-05-18 | $41.64 | 96,100 |
| 2026-05-15 | $41.75 | 102,500 |
| 2026-05-14 | $42.00 | 162,800 |
| 2026-05-13 | $41.80 | 74,400 |
| 2026-05-12 | $41.75 | 83,700 |
| 2026-05-11 | $41.50 | 119,400 |
| 2026-05-08 | $41.89 | 111,700 |
| 2026-05-07 | $41.29 | 194,900 |
| 2026-05-06 | $41.60 | 164,100 |
About XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
đ° Latest News
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-15T21:25:01Z
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-11T22:05:06Z
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-08T13:35:01Z
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T12:50:09Z
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T22:30:10Z
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
Zacks âĸ 2026-04-28T09:53:00Z
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
Investor's Business Daily âĸ 2026-04-27T20:11:01Z
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
The Wall Street Journal âĸ 2026-04-27T12:10:00Z
We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability
Simply Wall St. âĸ 2026-03-26T10:51:31Z
XOMA Royalty Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-18T23:20:30Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $11,660,000 | $10,220,000 | $4,758,000 | $6,027,000 |
| Operating Revenue | $11,660,000 | $10,220,000 | $4,758,000 | $6,027,000 |
| Expenses | ||||
| Interest Expense | $13,031,000 | $13,840,000 | $569,000 | $0 |
| Total Expenses | $276,000 | $50,196,000 | $28,221,000 | $23,441,000 |
| Other Income Expense | $33,462,000 | $34,337,000 | $-16,799,000 | $295,000 |
| Other Non Operating Income Expenses | $5,015,000 | $297,000 | $75,000 | $40,000 |
| Net Non Operating Interest Income Expense | $-13,031,000 | $-13,840,000 | $-569,000 | $0 |
| Interest Expense Non Operating | $13,031,000 | $13,840,000 | $569,000 | $0 |
| Operating Expense | $276,000 | $50,196,000 | $28,221,000 | $23,441,000 |
| Other Operating Expenses | $-40,489,000 | $-18,267,000 | - | - |
| General And Administrative Expense | $36,092,000 | $34,478,000 | $25,606,000 | $23,191,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $31,712,000 | $-13,821,000 | $-40,831,000 | $-17,104,000 |
| Net Interest Income | $-13,031,000 | $-13,840,000 | $-569,000 | $0 |
| Normalized Income | $3,265,000 | $-37,973,515 | $-23,957,000 | $-17,359,000 |
| Net Income From Continuing And Discontinued Operation | $31,712,000 | $-13,821,000 | $-40,831,000 | $-17,104,000 |
| Total Operating Income As Reported | $11,384,000 | $-39,976,000 | $-41,848,000 | $-17,414,000 |
| Average Dilution Earnings | $7,668,000 | - | - | $0 |
| Net Income Common Stockholders | $18,516,000 | $-19,293,000 | $-46,303,000 | $-22,576,000 |
| Net Income | $31,712,000 | $-13,821,000 | $-40,831,000 | $-17,104,000 |
| Net Income Including Noncontrolling Interests | $31,712,000 | $-13,821,000 | $-40,831,000 | $-17,104,000 |
| Net Income Continuous Operations | $31,712,000 | $-13,821,000 | $-40,831,000 | $-17,104,000 |
| Pretax Income | $31,815,000 | $-19,479,000 | $-40,831,000 | $-17,119,000 |
| Special Income Charges | $21,224,000 | $19,316,000 | $-18,385,000 | $0 |
| Operating Income | $11,384,000 | $-39,976,000 | $-23,463,000 | $-17,414,000 |
| Depreciation Amortization Depletion Income Statement | $2,961,000 | $206,000 | $897,000 | $97,000 |
| Depreciation And Amortization In Income Statement | $2,961,000 | $206,000 | $897,000 | $97,000 |
| Amortization Of Intangibles Income Statement | $2,961,000 | $206,000 | $897,000 | $97,000 |
| Per Share | ||||
| Diluted EPS | $1.46 | $-1.65 | $-4.04 | $-1.98 |
| Basic EPS | $1.53 | $-1.65 | $-4.04 | $-1.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $9,887,485 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $19,371,000 | $-39,463,000 | $-22,488,000 | $-17,270,000 |
| Total Unusual Items | $28,447,000 | $34,040,000 | $-16,874,000 | $255,000 |
| Total Unusual Items Excluding Goodwill | $28,447,000 | $34,040,000 | $-16,874,000 | $255,000 |
| Reconciled Depreciation | $2,972,000 | $216,000 | $900,000 | $104,000 |
| EBITDA (Bullshit earnings) | $47,818,000 | $-5,423,000 | $-39,362,000 | $-17,015,000 |
| EBIT | $44,846,000 | $-5,639,000 | $-40,262,000 | $-17,119,000 |
| Diluted Average Shares | $17,982,000 | $11,701,000 | $11,471,000 | $11,413,000 |
| Basic Average Shares | $12,081,000 | $11,701,000 | $11,471,000 | $11,413,000 |
| Diluted NI Availto Com Stockholders | $26,184,000 | $-19,293,000 | $-46,303,000 | $-22,576,000 |
| Otherunder Preferred Stock Dividend | $7,668,000 | - | - | $0 |
| Preferred Stock Dividends | $5,528,000 | $5,472,000 | $5,472,000 | $5,472,000 |
| Tax Provision | $103,000 | $-5,658,000 | $0 | $-15,000 |
| Restructuring And Mergern Acquisition | $-21,224,000 | $-19,316,000 | $0 | $0 |
| Gain On Sale Of Security | $7,223,000 | $14,724,000 | $1,511,000 | $255,000 |
| Provision For Doubtful Accounts | $0 | $30,904,000 | $1,575,000 | - |
| Amortization | $2,961,000 | $206,000 | $897,000 | $97,000 |
| Research And Development | $1,712,000 | $2,875,000 | $143,000 | $153,000 |
| Selling General And Administration | $36,092,000 | $34,478,000 | $25,606,000 | $23,191,000 |
| Other Gand A | $36,092,000 | $34,478,000 | $25,606,000 | $23,191,000 |
| Write Off | - | $0 | $14,253,000 | $0 |
| Other Special Charges | - | - | $4,132,000 | - |
| Impairment Of Capital Assets | - | - | $15,828,000 | $0 |
Fetched: 2026-05-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $39,185,000 | $35,993,000 | $88,721,000 | $108,864,000 |
| Total Assets | $272,698,000 | $221,277,000 | $234,301,000 | $140,382,000 |
| Total Non Current Assets | $155,439,000 | $95,673,000 | $64,988,000 | $79,129,000 |
| Other Non Current Assets | $49,388,000 | $8,507,000 | $64,585,000 | $63,943,000 |
| Non Current Accounts Receivable | $60,321,000 | $60,906,000 | $57,952,000 | $63,683,000 |
| Financial Assets | $697,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $44,756,000 | $25,909,000 | $0 | $15,150,000 |
| Other Intangible Assets | $44,756,000 | $25,909,000 | - | - |
| Current Assets | $117,259,000 | $125,604,000 | $169,313,000 | $61,253,000 |
| Other Current Assets | $852,000 | $2,076,000 | $483,000 | $725,000 |
| Restricted Cash | $5,441,000 | $1,330,000 | $160,000 | $0 |
| Receivables | $27,676,000 | $17,015,000 | $15,219,000 | $2,367,000 |
| Other Receivables | $22,780,000 | $15,176,000 | $14,215,000 | $2,366,000 |
| Accounts Receivable | $4,896,000 | $1,839,000 | $1,004,000 | $1,000 |
| Cash Cash Equivalents And Short Term Investments | $83,290,000 | $105,183,000 | $153,451,000 | $58,161,000 |
| Cash And Cash Equivalents | $82,908,000 | $101,654,000 | $153,290,000 | $57,826,000 |
| Investmentin Financial Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Taxes Receivable | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Net Debt | $26,069,000 | $16,615,000 | - | - |
| Total Debt | $131,555,000 | $119,198,000 | $124,450,000 | $34,000 |
| Long Term Debt And Capital Lease Obligation | $116,565,000 | $107,358,000 | $118,853,000 | $0 |
| Long Term Debt | $96,451,000 | $106,875,000 | $118,518,000 | - |
| Current Debt And Capital Lease Obligation | $14,990,000 | $11,840,000 | $5,597,000 | $34,000 |
| Current Debt | $12,526,000 | $11,394,000 | $5,543,000 | - |
| Other Current Borrowings | $12,526,000 | $11,394,000 | $5,543,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $188,757,000 | $159,375,000 | $145,580,000 | $16,368,000 |
| Total Non Current Liabilities Net Minority Interest | $153,937,000 | $135,001,000 | $126,081,000 | $9,550,000 |
| Other Non Current Liabilities | $14,057,000 | $3,214,000 | - | - |
| Non Current Deferred Liabilities | $3,296,000 | $4,410,000 | $7,228,000 | $9,550,000 |
| Non Current Deferred Taxes Liabilities | $103,000 | $0 | - | - |
| Current Liabilities | $34,820,000 | $24,374,000 | $19,499,000 | $6,818,000 |
| Other Current Liabilities | $5,045,000 | $3,000,000 | $7,000,000 | $75,000 |
| Current Deferred Liabilities | $1,268,000 | $1,361,000 | $2,113,000 | $1,899,000 |
| Payables And Accrued Expenses | $8,675,000 | $6,618,000 | $3,586,000 | $4,248,000 |
| Interest Payable | $2,777,000 | $3,039,000 | $535,000 | - |
| Payables | $3,632,000 | $2,701,000 | $2,021,000 | $1,892,000 |
| Dividends Payable | $1,424,000 | $1,368,000 | $1,368,000 | $1,368,000 |
| Total Tax Payable | $0 | $280,000 | $0 | $0 |
| Income Tax Payable | $0 | $280,000 | $0 | $0 |
| Accounts Payable | $2,208,000 | $1,053,000 | $653,000 | $524,000 |
| Equity | ||||
| Common Stock Equity | $83,892,000 | $61,853,000 | $88,672,000 | $123,965,000 |
| Preferred Stock Equity | $49,000 | $49,000 | $49,000 | $49,000 |
| Total Equity Gross Minority Interest | $83,941,000 | $61,902,000 | $88,721,000 | $124,014,000 |
| Stockholders Equity | $83,941,000 | $61,902,000 | $88,721,000 | $124,014,000 |
| Gains Losses Not Affecting Retained Earnings | $53,000 | $73,000 | $0 | - |
| Other Equity Adjustments | $53,000 | $73,000 | - | - |
| Retained Earnings | $-1,221,450,000 | $-1,237,057,000 | $-1,223,223,000 | $-1,182,392,000 |
| Preferred Securities Outside Stock Equity | $20,019,000 | $20,019,000 | - | - |
| Other | ||||
| Preferred Shares Number | $2,744,500 | $2,584,000 | $2,584,000 | $2,584,000 |
| Ordinary Shares Number | $11,858,955 | $11,952,377 | $11,495,492 | $11,454,025 |
| Share Issued | $11,858,955 | $11,952,377 | $11,495,492 | $11,454,025 |
| Tangible Book Value | $39,136,000 | $35,944,000 | $88,672,000 | $108,815,000 |
| Invested Capital | $192,869,000 | $180,122,000 | $212,733,000 | $123,965,000 |
| Working Capital | $82,439,000 | $101,230,000 | $149,814,000 | $54,435,000 |
| Capital Lease Obligations | $22,578,000 | $929,000 | $389,000 | $34,000 |
| Total Capitalization | $180,392,000 | $168,777,000 | $207,239,000 | $124,014,000 |
| Additional Paid In Capital | $1,305,200,000 | $1,298,747,000 | $1,311,809,000 | $1,306,271,000 |
| Capital Stock | $138,000 | $139,000 | $135,000 | $135,000 |
| Common Stock | $89,000 | $90,000 | $86,000 | $86,000 |
| Preferred Stock | $49,000 | $49,000 | $49,000 | $49,000 |
| Non Current Deferred Revenue | $3,193,000 | $4,410,000 | $7,228,000 | $9,550,000 |
| Long Term Capital Lease Obligation | $20,114,000 | $483,000 | $335,000 | $0 |
| Current Deferred Revenue | $1,268,000 | $1,361,000 | $2,113,000 | $1,899,000 |
| Current Capital Lease Obligation | $2,464,000 | $446,000 | $54,000 | $34,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,842,000 | $1,555,000 | $1,203,000 | $562,000 |
| Current Accrued Expenses | $5,043,000 | $3,917,000 | $1,565,000 | $2,356,000 |
| Net PPE | $277,000 | $351,000 | $403,000 | $36,000 |
| Gross PPE | $277,000 | $351,000 | $403,000 | $36,000 |
| Other Properties | $277,000 | $351,000 | $403,000 | $36,000 |
| Other Short Term Investments | $382,000 | $3,529,000 | $161,000 | $335,000 |
| Treasury Shares Number | - | - | $0 | - |
| Investments And Advances | - | - | - | - |
Fetched: 2026-05-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,854,000 | $-13,768,000 | $-18,175,000 | $-28,126,000 |
| Operating Activities | ||||
| Operating Cash Flow | $2,871,000 | $-13,748,000 | $-18,158,000 | $-12,879,000 |
| Cash Flow From Continuing Operating Activities | $2,871,000 | $-13,748,000 | $-18,158,000 | $-12,879,000 |
| Operating Gains Losses | $-3,615,000 | $118,000 | $123,000 | $85,000 |
| Investing Activities | ||||
| Capital Expenditure | $-20,725,000 | $-20,000 | $-17,000 | $-15,247,000 |
| Investing Cash Flow | $50,886,000 | $-28,259,000 | $-711,000 | $-20,221,000 |
| Cash Flow From Continuing Investing Activities | $50,886,000 | $-28,259,000 | $-711,000 | $-20,221,000 |
| Net Other Investing Changes | $56,397,000 | $-23,752,000 | $-694,000 | $-4,974,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-16,715,000 | $-13,000 | $0 | - |
| Issuance Of Capital Stock | $4,342,000 | $0 | - | $0 |
| Financing Cash Flow | $-26,463,000 | $-11,127,000 | $120,593,000 | $-4,451,000 |
| Cash Flow From Continuing Financing Activities | $-26,463,000 | $-11,127,000 | $120,593,000 | $-4,451,000 |
| Net Other Financing Charges | $-3,066,000 | $-3,954,000 | $-4,401,000 | $-1,398,000 |
| Cash Dividends Paid | $-5,472,000 | $-5,472,000 | $-5,472,000 | $-5,472,000 |
| Preferred Stock Dividend Paid | $-5,472,000 | $-5,472,000 | $-5,472,000 | $-5,472,000 |
| Net Preferred Stock Issuance | $3,347,000 | $0 | - | $0 |
| Preferred Stock Issuance | $4,019,000 | $0 | - | $0 |
| Net Common Stock Issuance | $-15,720,000 | $-13,000 | $0 | - |
| Common Stock Issuance | $323,000 | $0 | - | - |
| Other | ||||
| Repayment Of Debt | $-10,598,000 | $-6,902,000 | $0 | $0 |
| Interest Paid Supplemental Data | $11,906,000 | $9,985,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $277,000 | $0 | $0 | $76,000 |
| End Cash Position | $133,710,000 | $106,416,000 | $159,550,000 | $57,826,000 |
| Beginning Cash Position | $106,416,000 | $159,550,000 | $57,826,000 | $95,377,000 |
| Changes In Cash | $27,294,000 | $-53,134,000 | $101,724,000 | $-37,551,000 |
| Proceeds From Stock Option Exercised | $5,046,000 | $5,214,000 | $466,000 | $2,419,000 |
| Preferred Stock Payments | $-672,000 | $0 | - | - |
| Common Stock Payments | $-16,043,000 | $-13,000 | $0 | - |
| Net Issuance Payments Of Debt | $-10,598,000 | $-6,902,000 | $130,000,000 | $0 |
| Net Long Term Debt Issuance | $-10,598,000 | $-6,902,000 | $130,000,000 | $0 |
| Long Term Debt Payments | $-10,598,000 | $-6,902,000 | $0 | $0 |
| Net Investment Purchase And Sale | $6,900,000 | $-3,237,000 | $0 | - |
| Sale Of Investment | $6,999,000 | $0 | - | - |
| Purchase Of Investment | $-99,000 | $-3,237,000 | $0 | - |
| Net Business Purchase And Sale | $8,314,000 | $-1,250,000 | $0 | - |
| Sale Of Business | $8,314,000 | $18,926,000 | $0 | - |
| Purchase Of Business | $0 | $-20,176,000 | $0 | - |
| Net Intangibles Purchase And Sale | $-20,725,000 | $0 | $0 | $-15,247,000 |
| Purchase Of Intangibles | $-20,725,000 | $0 | $0 | $-15,247,000 |
| Net PPE Purchase And Sale | $0 | $-20,000 | $-17,000 | $0 |
| Purchase Of PPE | $0 | $-20,000 | $-17,000 | $0 |
| Change In Working Capital | $-11,370,000 | $-2,789,000 | $-3,529,000 | $-181,000 |
| Change In Other Working Capital | $-1,310,000 | $-3,570,000 | $-2,108,000 | $-1,877,000 |
| Change In Other Current Liabilities | $-876,000 | $-284,000 | $-114,000 | $-195,000 |
| Change In Payables And Accrued Expense | $-10,597,000 | $1,598,000 | $-523,000 | $1,754,000 |
| Change In Prepaid Assets | $3,839,000 | $302,000 | $219,000 | $-71,000 |
| Change In Receivables | $-2,426,000 | $-835,000 | $-1,003,000 | $208,000 |
| Other Non Cash Items | $-26,094,000 | $-2,068,000 | $1,653,000 | $170,000 |
| Stock Based Compensation | $9,273,000 | $10,312,000 | $9,099,000 | $3,608,000 |
| Unrealized Gain Loss On Investment Securities | $-110,000 | $-58,000 | $174,000 | $439,000 |
| Deferred Tax | $103,000 | $-5,658,000 | $0 | - |
| Deferred Income Tax | $103,000 | $-5,658,000 | $0 | - |
| Depreciation Amortization Depletion | $2,972,000 | $216,000 | $900,000 | $104,000 |
| Depreciation And Amortization | $2,972,000 | $216,000 | $900,000 | $104,000 |
| Amortization Cash Flow | $2,961,000 | $206,000 | $897,000 | $97,000 |
| Amortization Of Intangibles | $2,961,000 | $206,000 | $897,000 | $97,000 |
| Depreciation | $11,000 | $10,000 | $3,000 | $7,000 |
| Pension And Employee Benefit Expense | $141,000 | $118,000 | $123,000 | $85,000 |
| Gain Loss On Investment Securities | $-3,756,000 | - | - | - |
| Net Income From Continuing Operations | $31,712,000 | $-13,821,000 | $-40,831,000 | $-17,104,000 |
| Issuance Of Debt | - | $0 | $130,000,000 | $0 |
| Long Term Debt Issuance | - | $0 | $130,000,000 | $0 |
| Change In Payable | - | $1,598,000 | $-523,000 | $1,754,000 |
| Change In Account Payable | - | $1,598,000 | $-523,000 | $1,845,000 |
| Asset Impairment Charge | - | $0 | $14,253,000 | $0 |
| Gain Loss On Sale Of Business | - | $-19,316,000 | $0 | - |
| Change In Tax Payable | - | - | $0 | $-91,000 |
| Change In Income Tax Payable | - | - | $0 | $-91,000 |
| Sale Of Intangibles | - | - | - | $3,026,000 |
| Changes In Account Receivables | - | - | - | $208,000 |
Fetched: 2026-05-24